Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr Muhammad Ali Memon as its Chief Medical Officer, effective 1st January 2025. Dr. Memon is a qualified ophthalmologist and joins CTx from AAVantgarde Bio, where he held the position of Vice President, Clinical Science and Safety. Prior to AAVantgarde, …
Explore